Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: A competing risk analysis

Pinto, 2016, Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases, Eur. Heart J., 37, 1850, 10.1093/eurheartj/ehv727 Goldberger, 2014, Sudden cardiac death risk stratification in dilated cardiomyopathy: climbing the pyramid of knowledge, Circ. Arrhythm. Electrophysiol., 7, 1006, 10.1161/CIRCEP.114.002395 Gorgels, 2003, Out-of-hospital cardiac arrest—the relevance of heart failure. The Maastricht Circulatory Arrest Registry, Eur. Heart J., 24, 1204, 10.1016/S0195-668X(03)00191-X Al-Khatib, 2018, 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, Circulation, 138, e272 Kober, 2016, Defibrillator implantation in patients with nonischemic systolic heart failure, N. Engl. J. Med., 375, 1221, 10.1056/NEJMoa1608029 Ponikowski, 2016, Eur. J. Heart Fail., 18, 891, 10.1002/ejhf.592 Bansch, 2002, Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT), Circulation, 105, 1453, 10.1161/01.CIR.0000012350.99718.AD Bardy, 2005, Sudden cardiac death in heart failure trial I. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure, N. Engl. J. Med., 352, 225, 10.1056/NEJMoa043399 Kadish, 2004, Defibrillators in non-ischemic cardiomyopathy treatment evaluation I. prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy, N. Engl. J. Med., 350, 2151, 10.1056/NEJMoa033088 Strickberger, 2003, Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT, J. Am. Coll. Cardiol., 41, 1707, 10.1016/S0735-1097(03)00297-3 Merlo, 2014, Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years, Eur. J. Heart Fail., 16, 317, 10.1002/ejhf.16 Elliott, 2008, Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases, Eur. Heart J., 29, 270, 10.1093/eurheartj/ehm342 Mestroni, 1999, Guidelines for the study of familial dilated cardiomyopathies. Collaborative research group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy, Eur. Heart J., 20, 93, 10.1053/euhj.1998.1145 Lang, 2015, Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J. Am. Soc. Echocardiogr., 28, 1, 10.1016/j.echo.2014.10.003 Nagueh, 2016, Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J. Am. Soc. Echocardiogr., 29, 277, 10.1016/j.echo.2016.01.011 Hicks, 2015, Circulation, 132, 302, 10.1161/CIR.0000000000000156 R Core Team (2014), 2014 Lewis, 2017, Health-related quality of life outcomes in PARADIGM-HF, Circ Heart Fail, 10, 10.1161/CIRCHEARTFAILURE.116.003430 Priori, 2015, Eur. Heart J., 36, 2793, 10.1093/eurheartj/ehv316 Shen, 2017, Declining risk of sudden death in heart failure, N. Engl. J. Med., 377, 41, 10.1056/NEJMoa1609758 Rush, 2015, Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials, JACC Heart Fail, 3, 603, 10.1016/j.jchf.2015.03.013 Stecker, 2006, Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon sudden unexpected death study, J. Am. Coll. Cardiol., 47, 1161, 10.1016/j.jacc.2005.11.045 Friedman, 2017, New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: a pooled analysis of 4 randomized controlled trials, Am. Heart J., 191, 21, 10.1016/j.ahj.2017.06.002 Gigli, 2019, Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy, J. Am. Coll. Cardiol., 74, 1480, 10.1016/j.jacc.2019.06.072 Spezzacatene, 2015, Arrhythmogenic phenotype in dilated cardiomyopathy: natural history and predictors of life-threatening arrhythmias, J. Am. Heart Assoc., 4, 10.1161/JAHA.115.002149